Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Lymphoma, Non-Hodgkin 5Multiple Myeloma 4Melanoma 3Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Solid Tumors 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immune-related Adverse Events 1Hematologic Neoplasms 1Glioblastoma 1Craniopharyngioma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Breast Neoplasms 1Bone Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 41Radiotherapy 19Radiation 12Nivolumab 10pembrolizumab 8Magnetic Resonance Spectroscopy 8Bevacizumab 7Specimen Handling 6poly ICLC 4atezolizumab 4Lomustine 4Ipilimumab 4Surgical Procedures, Operative 3Photons 3Immunoglobulin G 3Disulfides 3Cyclophosphamide 3veliparib 2sargramostim 2rocakinogene sifuplasmid 2olaparib 2niraparib 2Transurethral Resection of Bladder 2Surveys and Questionnaires 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2OKN 007 2Mycophenolic Acid 2Metformin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Glioblastoma × tocilizumab × Clear all
NCT04729959 2026-04-01

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
59 enrolled
CNS

Astrocytoma, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡